Terrance P. Coyne, EVP & CFO at Royalty Pharma plc (RPRX), sold 487,082 shares at $42.08 ($20.7M) on 2026-02-02, disclosed to the SEC on 2026-02-04.
Open-market sale of $20.7M RPRX by EVP & CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.08 | 5,843 | $246K | 1.2% |
| 2 | $42.08 | 102,581 | $4.3M | 20.8% |
| 3 | $42.08 | 5,843 | $246K | 1.2% |
| 4 | $42.08 | 102,581 | $4.3M | 20.8% |
| 5 | $42.84 | 108,759 | $4.7M | 22.5% |
| 6 | $42.84 | 6,195 |
| $265K |
| 1.3% |
| 7 | $42.84 | 6,195 | $265K | 1.3% |
| 8 | $42.84 | 108,759 | $4.7M | 22.5% |
| 9 | $43.29 | 1,087 | $47K | 0.2% |
| 10 | $43.29 | 19,076 | $826K | 4.0% |
| 11 | $43.29 | 1,087 | $47K | 0.2% |
| 12 | $43.29 | 19,076 | $826K | 4.0% |
| Total | $42.54 avg | 487,082 | $20.7M | 100% |
| Filing → |
| RPRX | SELL | 2026-04-30 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-04-02 | $1.7M | — | Filing → |
| RPRX | SELL | 2026-03-25 | $3.2M | — | Filing → |